Cancers · 2023 · 21 citations · 48 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCheckpoint Inhibitor TherapyImmune Cell InfiltrationImmune Checkpoint InhibitorsImmunotherapy For Skin CancerT Cell Responses To TumorsTumor Immune Microenvironment3D Tumor ModelsImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyImmuno-oncology ModelsModeling Tumor MicroenvironmentTumor Immunology ModelingTumor Microenvironment EffectsTumor Microenvironment Modeling
Melanoma is responsible for the majority of skin cancer-related fatalities. Immune checkpoint inhibitor (ICI) treatments have revolutionized the management of the disease by significantly increasing patient survival rates. However, a considerable number of tumors treated with these drugs fail to respond or may develop resistance over time. Tumor growth and its response to therapies are critically influenced by the tumor microenvironment (TME); it directly supports cancer cell growth and influences the behavior of surrounding immune cells, which can become tumor-permissive, thereby rendering immunotherapies ineffective. Ex vivo modeling of melanomas and their response to treatment could significantly advance our understanding and predictions of therapy outcomes. Efforts have been directed toward developing reliable models that accurately mimic melanoma in its appropriate tissue environment, including tumor organoids, bioprinted tissue constructs, and microfluidic devices. However, incorporating and modeling the melanoma TME and immune component remains a significant challenge. Here, we review recent literature regarding the generation of in vitro 3D models of normal skin and melanoma and the approaches used to incorporate the immune compartment in such models. We discuss how these constructs could be combined and used to test immunotherapies and elucidate treatment resistance mechanisms. The development of 3D in vitro melanoma models that faithfully replicate the complexity of the TME and its interaction with the immune system will provide us with the technical tools to better understand ICI resistance and increase its efficacy, thereby improving personalized melanoma therapy.
48
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.7K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +14
Organoid Modeling of the Tumor Immune Microenvironment
James T. Neal, Xingnan Li, Junjie Zhu et al. · Cell · 2018 · 1.5K citations · Full text